Its role Owner
Johnson & Johnson is a U.S.-based multinational healthcare company headquartered in New Brunswick, New Jersey. It operates through two primary segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). The company discovers, develops, manufactures, and markets prescription therapeutics and medical technologies worldwide, with focus areas that include oncology, immunology, neuroscience, infectious diseases, cardiovascular and metabolism, and pulmonary hypertension. Janssen Biotech, Inc., and related Janssen entities form part of its pharmaceutical operations.
From a chemicals and manufacturing perspective, Johnson & Johnson’s pharmaceutical business spans small-molecule active pharmaceutical ingredient (API) synthesis, biologics and monoclonal antibody production, and sterile, parenteral, and solid-dose drug product manufacturing. These activities are supported by a global R&D and GMP manufacturing network, alongside extensive external partnerships and licensing arrangements. The company maintains large-scale quality, regulatory, and supply chain capabilities to supply medicines to markets worldwide.
Also known as Janssen Biotech, Inc..
chemXplore tracks 2 projects involving J&J, of which 2 are active.
Closest to start-up first.
Cohort 5 reported 77% confirmed ORR (14% CR) in non‑HPV HNSCC with subcutaneous amivantamab + pembrolizumab and carboplatin; median follow‑up 10.6 months; safety consistent with known profiles.
Phase 1 data show 75% imaging response and deep PSA declines at 50 mg; most adverse events were mild–moderate and 50 mg will advance to Phase 2.
Apalutamide plus short-course ADT given six months around prostatectomy improved event-free and metastasis-free survival and delayed need for additional therapy in a 408‑patient randomized substudy.
New clinical results include first-in-human data for oral RIPTAC JNJ-6143 in mCRPC, late-breaking PROTEUS Phase 3 prostate results, and expanded RYBREVANT FASPRO datasets across lung and head & neck cancers.
In FUZION, TREMFYA 100 mg q8w combined remission rose from 28% at Week 24 to 35% at Week 48; 200 mg q4w rates remained stable and safety was consistent through one year.
CHMP recommends talquetamab (TALVEY) with daratumumab ± pomalidomide for adults with relapsed/refractory multiple myeloma after ≥1 prior therapy, supported by MonumenTAL-3 efficacy and survival data.
Phase 3 GALAXI 2 and 3 Week 144 LTE data report high rates of clinical, corticosteroid‑free and endoscopic remission with two maintenance regimens; 74% remained on treatment at three years.
Phase 3 data show sustained PASI90/PASI100 and IGA 0/1 responses to Week 112, durable itch improvement, and no new safety signals.
active all projects
